GHENT, Belgium, 27 April 2008 - Ablynx [Euronext Brussels: ABLX], a
pioneer in the discovery and development of Nanobodies®, a novel
class of antibody-derived therapeutic proteins, has announced that Dr
Hennie Hoogenboom will be stepping down from his position as Chief
Scientific Officer and member of the Executive Committee.
Dr Hoogenboom joined Ablynx in 2005 and has contributed significantly
to building up the robust Nanobody® technology platform and to the
discovery of Nanobodies® for internal and partnered therapeutic
programmes. Dr Hoogenboom will work closely together with the
Executive Committee to assure an effective and smooth transition of
responsibilities.
Dr Edwin Moses, Chief Executive Officer and Chairman commented: "I
wish to thank Hennie for his contribution to Ablynx. We appreciate
his contributions and wish him well in his future endeavors." In line
with its strategy to transition from a technology platform to a
product Company, Ablynx has initiated an executive search to
strengthen its senior management team with individuals with extensive
experience in the discovery and development of pharmaceuticals.
Commenting on this search, Dr Moses said: "With its extensive
resources, excellent validated biologics platform technology and
developing product pipeline, Ablynx offers unique opportunities to
the right individuals."
Hennie Hoogenboom commented: "Working at Ablynx for the past years
has been an extraordinary and unique opportunity, with the Company
growing from a small biotech firm to a public company with multiple
large partnerships with pharmaceutical companies, I'm honored to have
been part of this phase of the Company and to have worked with such
talented and dedicated colleagues."
As the Company continues to advance its product portfolio to grow a
broader product pipeline, its aim is to file 5 IND-equivalents over
the next 5 years. Ablynx's lead programme, ALX-0081 has successfully
completed a first Phase I study and the Company is progressing this
development candidate to the next stage, with a Phase 1b multi-dose
study in patients due to start shortly.
-ends-
For more information, please contact:
College Hill Life Sciences - for UK/International media enquiries:
Sue Charles, Justine Lamond, John Mc Intyre
t: +44 (0)20 7457 2020
f: +44 (0)20 7866 7900
e: ablynx@collegehill.com
Ablynx:
Dr. Edwin Moses
Chairman and CEO
t: +32 (0)9 262 00 07
m: +44 (0)7771 954 193 / +32 (0)473 39 50 68
e: edwin.moses@ablynx.com
Eva-Lotta Allan
Chief Business Officer
t: +32 (0)9 262 00 75
m: +32 (0)475 78 36 21 / +44 (0)7990 570 900
e: eva-lotta.allan@ablynx.com
http://hugin.info/137912/R/1213754/252527.pdf
Copyright © Hugin AS 2008. All rights reserved.
bourse
